Traws Pharma, Inc. — Director's Dealing 2023

Feb 8, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2023-02-07

Reporting Person: Gelder Mark S. MD (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-07	Common Stock	M	5833	—	Acquired	11729	Direct
2023-02-07	Common Stock	F	1242	$1.36	Disposed	10487	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-07	Restricted Stock Units	$	M	5833	Disposed		Common Stock (5833)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: On February 7, 2022 the reporting person was granted 17,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.